All Stories

  1. Comment on: NETs in the spotlight: exploring NETosis markers for tracking disease activity in IgA vasculitis
  2. Concerns Regarding Use of High-Dose Cyclosporine in the Management of Refractory Chronic Spontaneous Urticaria
  3. Role of Thymic Dysfunction in the Pathogenesis of Lichen Planus
  4. British Society for Allergy and Immunology Abstracts From the 2024 Annual Conference
  5. Comment on: Evaluation of the ACR/EULAR 2022 criteria for classification of ANCA-associated vasculitis in a population-based cohort from Sweden
  6. Comment on: van der Rijst LP et al
  7. Comment on: van der Rijst LP et al.
  8. Tumid lupus erythematosus in C1-inhibitor deficiency
  9. Comment on Tuten Dal S et al
  10. Comment on Tuten Dal S et al
  11. Deciding noninferiority margins for non–intramuscular adrenaline delivery systems
  12. Route and dosage of intramuscular-alternative epinephrine delivery systems remains undetermined
  13. Whole blood immune memory cells is not sufficient to predict SARS-CoV-2 vaccine responsiveness
  14. Immunomodulation mediated by polyclonal IgG replacement in patients with chronic lymphocytic leukemia may be important in infection prevention
  15. Resistant Chronic Spontaneous Urticaria – A Case Series Narrative Review of Treatment Options
  16. Interstitial lung disease in common variable immunodeficiency
  17. BSACI Registry for Immunotherapy (BRIT): Providing safe and effective immunotherapy for allergies and urticaria
  18. Comment on: Gudu T, Stober C, Cope AP et al. Baricitinib set to join the Covid-19 therapeutic arsenal?
  19. Ibrutinib does not reverse disease- and treatment-related hypogammaglobulinaemia associated with chronic lymphocytic leukemia
  20. Evaluating sensitization patterns on ImmunoCAP-detected polysensitized patients with microarray-based multiplex assay (ISAC)
  21. Using National Registries to Identify Targeted Therapies for Refractory Urticaria
  22. Epigenetic alterations on C1-inhibitor expression may influence hereditary angioedema attack frequency and C4 levels
  23. Emerging and Reemerging Sexually Transmitted Infections
  24. Mast cell tryptase level should be checked in all patients with suspected Kounis syndrome
  25. Anti-phospholipid syndrome and valvular pathology
  26. Omalizumab retreatment rates in chronic spontaneous urticaria
  27. Comment on: Vaginal dryness in primary Sjögren’s syndrome: a histopathological case–control study
  28. Understanding the cholesterol and cytokine network in patients with adrenal insufficiency and cirrhosis
  29. Chlorhexidine in swabs - friend or foe?
  30. Do ribosomal protein alterations affect ER stress response in CVID?
  31. Comment on Bertrand et al
  32. JAK Inhibition with Methotrexate as Treatment for COVID-19 Is a Double-Edged Sword
  33. Role of translational controlled tumor protein in omalizumab resistance
  34. Urticaria in patients with diabetes: Adverse drug reaction or relapse of underlying autoimmune urticaria?
  35. Testing for Fecal Calprotectin in Food Protein–Induced Enterocolitis Syndrome
  36. Aspergillus fumigatus IgG level greater than 60 mg/L Increases Diagnostic Specificity of Allergic Bronchopulmonary Aspergillosis
  37. Indolent systemic mastocytosis manifesting as protracted anaphylactic shock
  38. Chronic Urticarial Vasculitis and Immunoglobulin-G Monoclonal Gammopathy: Variant Schnitzler Syndrome
  39. Celiac Disease in Children – A Profile from a Predominantly Rice Eating Population
  40. Evidence of Parthenium sensitivity across all seasons in patients from middle and lower gangetic regions
  41. Chronic granulomatous disease may be an underlying cause for invasive nocardiosis
  42. Letter in response to previous publication in IJD® Drug-induced CD30+skin lesions: Complex interplay between infectious agents, human leukocyte antigen system and mast cells/T cells
  43. Does immunoglobulin therapy have a role in treating Dengue virus infection with induced systemic capillary leak syndrome?
  44. Low calculated globulin to identify unsuspected antibody deficiency
  45. Antiphospholipid syndrome is an important modifiable risk factor of stroke in the young
  46. Persistent cow′s milk allergy with attacks of anaphylaxis
  47. Helicobacter Pylori Associated Urticarias
  48. Raised immunoglobulin E levels are not predictive of allergic reactions to blood products
  49. The Pitfalls of FeNO Testing
  50. Ocular manifestations of the antineutrophil cytoplasmic antibody and antiphospholipid syndromes
  51. Comparison of Cytokine Responses with Anti-D and Intravenous Immunoglobulin in Idiopathic Thrombocytopenia
  52. More robust evidence and safety checks are required before autologous serum therapy as treatment for chronic urticaria can be recommended
  53. Chronic Urticaria: Indian Context—Challenges and Treatment Options
  54. Allergic diseases of the skin and drug allergies – 2021. Efficacy of montelukast as add-on therapy in patients with chronic idiopathic urticaria
  55. Efficacy of Montelukast as Added Therapy in Patients with Chronic Idiopathic Urticaria
  56. Reply
  57. Reply
  58. The Finding of Anticardiolipin Autoantibodies in Patients With Pseudoexfoliation Syndrome Requires Further Evaluation
  59. Abnormal IL‐7 signaling may lead to the loss of bone mineral density in common variable immunodeficiency
  60. Chronic urticaria and use of statins
  61. Should we be giving enhanced vitamin D intakes to all?
  62. The role of hypoxia-inducible factor-1 alpha in TEMPI syndrome
  63. PLA2 receptor autoantibodies, complement activation and podocyte damage
  64. Letters to the editor
  65. Expanding indications of omalizumab therapy in the absence of specific IgE
  66. Serum Trough IgG level and Annual Intravenous Immunoglobulin Dose Are Not Related to Body Size in Patients on Regular Replacement Therapy
  67. Regulatory T-Cell Detection by Flow Cytometry and Systemic Sclerosis
  68. Administering intravenous immunoglobulin during infection is associated with infusion reactions in selected patients
  69. Do ribosomopathies explain some cases of common variable immunodeficiency?
  70. Anti-acetylcholine receptor antibody reactivity of IgG in commercial immunoglobulin preparations
  71. Recurrent infections with Aspergillus require exclusion of defects in the phagocyte NADPH oxidase pathway
  72. Anti-IL-5 therapy and DRESS
  73. Systemic Capillary Leak Syndrome Should be Considered in the Differential Diagnosis of Multi-Organ Failure and Hypovolemic Shock
  74. Mutations in STAT3 and diagnostic guidelines for hyper-IgE syndrome
  75. Pitfalls in the Diagnosis of Latex Allergy
  76. The Epithelial Mucin (MUC1) and Virus-Specific Antibodies Target Cell-Free Human Immunodeficiency Virus in Human Breast Milk
  77. Warfarin can be safe and effective in the extreme elderly
  78. Reply
  79. Pharmacotherapy for gastric antral vascular ectasia: dramatic response to tranexamic acid
  80. Lichen planus in a case of Good's syndrome (thymoma and immunodeficiency)
  81. Limited value of testing for intrinsic factor antibodies with negative gastric parietal cell antibodies in pernicious anaemia: Figure 1
  82. Intravenous immunoglobulin-induced neutropenia
  83. A Patient Survey on the Use and Effectiveness of Aerosolized Epinephrine (Primatene mist inhaler) for Treatment of Anaphylaxis/angioedema
  84. Comparison of Commercial Nonammoniated and Ammoniated Latex Skin Prick Testing Solutions by SDS-PAGE
  85. Invasive cryptococcus infections in immunocompetent individuals may suggest defects in CD40/CD40L signaling pathway
  86. Both autoantibodies and pathogen-specific antibodies are present in immunoglobulin preparations and reflect characteristics of the donor population
  87. The value of total IgE levels in the context of specific allergy
  88. Cardiac complications may be higher with use of proteasome inhibitors in patients with rheumatoid arthritis
  89. Hypoxia and Alzheimer disease
  90. The clinical significance of antinucleolar antibodies
  91. Both patient characteristics and IVIG product‐specific mechanisms may affect eosinophils in immunoglobulin‐treated Kawasaki disease
  92. Some cases of common variable immunodeficiency may be due to a mutation in the SBDS gene of Shwachman–Diamond syndrome
  93. Abnormal O-glycosylation of CD43 may account for some features of Wiskott-Aldrich syndrome
  94. Nimesulide and adverse drug reactions
  95. Risks of Intravenous Immunoglobulin in Sepsis Affect Trial Design
  96. Could oral spleen tyrosine kinase inhibitors lead to neoplastic transformation?
  97. Secondary systemic lupus erythematosus: An analysis of 4 cases of uncontrolled hereditary angioedema
  98. Metronidazole-Induced Aseptic Meningitis during Helicobacter pylori Eradication Therapy
  99. The Clinical Significance Of Isolated Antinucleolar Antibodies
  100. Clinical utility of the Coombs test
  101. CORRECTION
  102. Hepatitis C: reviewing the options
  103. Oral immunosuppressive drugs
  104. Early indicators of immunodeficiency in adults and children: protocols for screening for primary immunological defects
  105. Musculoskeletal and myotoxic side-effects in a patient treated for psoriasis
  106. Use of amino terminal type III procollagen peptide (P3NP) assay in methotrexate therapy for psoriasis
  107. Conjugate vaccines and polysaccharide response
  108. Biopeptides and immune exclusion
  109. Persistence of Natural Killer (NK) cell lymphocytosis with hyposplenism without development of leukaemia
  110. Psoriasis